Diosmin
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
DIOSMIN: From Chronic Venous Insufficiency to Amenorrhea
One-Sentence Summary
DIOSMIN is a flavonoid glycoside best known as a component of Daflon® (diosmin + hesperidin), approved in Europe for the treatment of chronic venous insufficiency. The TxGNN model predicts it may be effective for Amenorrhea, with a prediction score of 99.42% — however, no clinical trials and no published literature currently support this specific direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic venous insufficiency (Daflon®, Europe) |
| Predicted New Indication | Amenorrhea |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L5 |
| Saudi Arabia Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
DIOSMIN is a flavonoid glycoside (phytochemical) with known phytoestrogenic properties. It can weakly bind to estrogen receptors (ERα/ERβ) and inhibit COX-mediated prostaglandin E2 synthesis, which in turn affects uterine endometrial vascular permeability. These properties provide a plausible, if indirect, biological bridge to menstrual cycle regulation.
The TxGNN model likely derived this association through one of two hypothetical pathways: (1) venous tone modulation → endometrial blood flow → menstrual cycle, or (2) antioxidant activity → hypothalamic-pituitary-ovarian (HPO) axis protection. Both are mechanistically plausible at a theoretical level, as disrupted HPO axis signaling and poor uterine perfusion are recognized contributors to amenorrhea.
However, it is critical to note that these remain speculative mechanistic pathways. DIOSMIN's primary approved use — chronic venous insufficiency — has no established pharmacological link to menstrual disorders. This prediction is driven entirely by the graph neural network model and has not been validated by any clinical study or published research to date.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Saudi Arabia Market Information
DIOSMIN is currently not marketed in Saudi Arabia and holds no regulatory authorizations. No license records are available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is based solely on the TxGNN graph model (Evidence Level L5) with no supporting clinical trials or published literature. The mechanistic link between DIOSMIN and amenorrhea remains entirely theoretical, and DIOSMIN is not even marketed in Saudi Arabia, making clinical deployment premature.
To proceed, the following is needed:
- Systematic literature review for DIOSMIN (or Daflon®) in menstrual disorders, HPO axis modulation, or gynecological conditions
- Preclinical studies (animal models) demonstrating estrogenic or menstrual-cycle effects of DIOSMIN
- Mechanistic validation: confirm ERα/ERβ binding affinity and functional relevance at therapeutic doses
- Safety data: obtain full package insert warnings, contraindications, and drug interaction profile
- Regulatory pathway assessment: determine whether DIOSMIN can be registered in Saudi Arabia and under what indication framework
- If preclinical data is favorable, design a Phase 2 pilot study before any clinical decision
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.